1EAS

NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 3. DESIGN, SYNTHESIS, X-RAY CRYSTALLOGRAPHIC ANALYSIS, AND STRUCTURE-ACTIVITY RELATIONSHIPS FOR A SERIES OF ORALLY ACTIVE 3-AMINO-6-PHENYLPYRIDIN-2-ONE TRIFLUOROMETHYL KETONES


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Work: 0.183 
  • R-Value Observed: 0.183 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Nonpeptidic inhibitors of human leukocyte elastase. 3. Design, synthesis, X-ray crystallographic analysis, and structure-activity relationships for a series of orally active 3-amino-6-phenylpyridin-2-one trifluoromethyl ketones.

Bernstein, P.R.Andisik, D.Bradley, P.K.Bryant, C.B.Ceccarelli, C.Damewood Jr., J.R.Earley, R.Edwards, P.D.Feeney, S.Gomes, B.C.Kosmider, B.J.Steelman, G.B.Thomas, R.M.Vacek, E.P.Veale, C.A.Williams, J.C.Wolanin, D.J.Woolson, J.A.

(1994) J Med Chem 37: 3313-3326

  • DOI: 10.1021/jm00046a016
  • Primary Citation of Related Structures:  
    1EAS

  • PubMed Abstract: 
  • A series of nonpeptidic inhibitors of human leukocyte elastase (HLE) is reported. These trifluoromethyl ketone-based inhibitors contain a 3-amino-6-phenylpyridone group as a central template. The effect of varying the N-3 substituent in these inhibitors on in vitro potency, physical properties, and oral activity in a hamster based, HLE-induced lung damage model is described ...

    A series of nonpeptidic inhibitors of human leukocyte elastase (HLE) is reported. These trifluoromethyl ketone-based inhibitors contain a 3-amino-6-phenylpyridone group as a central template. The effect of varying the N-3 substituent in these inhibitors on in vitro potency, physical properties, and oral activity in a hamster based, HLE-induced lung damage model is described. The variety of substituents at this position that have little effect on in vitro potency supports the idea that this region of the molecule does not interact strongly with the enzyme. One exception to this generality is 13k, which is substituted with a (4-acetamidophenyl)sulfonyl group. This compound has a K(i) of 0.7 nM and is, in vitro, the most potent inhibitor in the series. In contrast, variation of the N-3 substituent was found to have a dramatic effect on activity after oral administration. Several analogs, including the parent amine, 7, formamide, 2u, benzyl sulfamide, 13e, and benzyl sulfonamide, 13f, show significant activity when administered at an oral dose of 2.5 mg/kg. Support for the modeling-based design concepts was obtained through in vitro SAR results and X-ray crystallographic analysis of the complex between 13d and porcine pancreatic elastase (PPE), a closely related enzyme.


    Related Citations: 
    • Nonpeptidic Inhibitors of Human Leukocyte Elastase. 6. Design of a Potent, Intratracheally Active, Pyridone-Based Trifluoromethyl Ketone
      Bernstein, P.R., Gomes, B.C., Kosmider, B.J., Vacek, E.P., Williams, J.C.
      () To be published --: --
    • Nonpeptidic Inhibitors of Human Leukocyte Elastase. 5. Design, Synthesis, and X-Ray Crystallography of a Series of Orally Active 5-Amino-Pyrimidin-6-One-Containing Trifluoromethylketones
      Veale, C.A., Bernstein, P.R., Bryant, C., Ceccarelli, C., Damewood, J.R., Earley, R., Feeney, S.W., Gomes, B., Kosmider, B.J., Steelman, G.B., Thomas, R.M., Vacek, E.P., Williams, J.C., Wolanin, D.J., Woolson, S.
      () To be published --: --
    • Nonpeptidic Inhibitors of Human Leukocyte Elastase. 4. Design, Synthesis,in Vitro, and in Vivo Activity of a Series of Beta-Carbolinone-Containing Trifluoromethyl Ketones
      Veale, C.A., Damewood, J.R., Steelman, G.B., Bryant, C., Gomes, B., Williams, J.
      () To be published --: --
    • Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis and in Vitro Activity of a Series of 3-Amino-6-Arylpyridin-2-One Trifluoromethyl Ketones
      Damewood, J.R., Edwards, P.D., Feeney, S., Gomes, B.C., Steelman, G.B., Tuthill, P.A., Warner, P., Williams, J.C., Woolson, S.A., Wolanin, D., Veale, C.
      (1994) J Med Chem 37: 3303
    • Nonpeptidic Inhibitors of Human Leukocyte Elastase. 1. The Design and Synthesis of Pyridone-Containing Inhibitors
      Warner, P., Green, R.C., Gomes, B.C., Williams, J.C.
      (1994) J Med Chem 37: 3090
    • Design of Orally Active, Nonpeptidic Inhibitors of Human Leukocyte Elastase
      Brown, F.J., Andisik, D.W., Bernstein, P.R., Bryant, C.B., Ceccarelli, C., Damewood, J.R., Edwards, P.D., Earley, R., Feeney, S.W., Green, R.C., Gomes, B., Kosmider, B.J., Krell, R., Shaw, A., Steelman, G.B., Thomas, R.M., Vacek, E.P., Veale, C.A., Tuthill, P.A., Warner, P., Williams, J.C., Wolanin, D.J., Woolson, S.A.
      (1994) J Med Chem 37: 1259
    • Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl Alpha-Ketobenzoxazoles,and the X-Ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole
      Edwards, P.D., Meyer, E.F., Vijayalakshmi, J., Tuthill, P.A., Andisik, D.A., Gomes, B., Strimpler, A.
      (1992) J Am Chem Soc 114: 1854
    • Crystal Structure of the Covalent Complex Formed by a Peptidyl Alpha,Alpha-Difluoro-Beta-Keto Amide with Porcine Pancreatic Elastase at 1.78-Angstrom Resolution
      Takahashi, L.H., Radhakrishnan, R., Rosenfield, R.E., Meyer, E.F., Trainor, D.A.
      (1989) J Am Chem Soc 111: 3368
    • X-Ray Diffraction Analysis of the Inhibition of Porcine Pancreatic Elastase by a Peptidyl Trifluoromethylketone
      Takahashi, L.H., Radhakrishnan, R., Rosenfield, R.E., Meyer, E.F., Trainor, D.A., Stein, M.
      (1988) J Mol Biol 201: 423

    Organizational Affiliation

    Zeneca Pharmaceuticals Group, A Business Unit of ZENECA Inc., Wilmington, Delaware 19897.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
PORCINE PANCREATIC ELASTASEA240Sus scrofaMutation(s): 0 
Gene Names: CELA1ELA1
EC: 3.4.21.36
UniProt
Find proteins for P00772 (Sus scrofa)
Explore P00772 
Go to UniProtKB:  P00772
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
TFK (Subject of Investigation/LOI)
Query on TFK

Download Ideal Coordinates CCD File 
F [auth A]3-[[(METHYLAMINO)SULFONYL]AMINO]-2-OXO-6-PHENYL-N-[3,3,3-TRIFLUORO-1-(1-METHYLETHYL)-2-OXOPHENYL]-1(2H)-PYRIDINE ACETAMIDE
C20 H23 F3 N4 O5 S
MYFMPKCOIMRDDD-KRWDZBQOSA-N
 Ligand Interaction
SO4
Query on SO4

Download Ideal Coordinates CCD File 
C [auth A], D [auth A], E [auth A]SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
NA
Query on NA

Download Ideal Coordinates CCD File 
B [auth A]SODIUM ION
Na
FKNQFGJONOIPTF-UHFFFAOYSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
TFK PDBBind:  1EAS Ki: 18 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Work: 0.183 
  • R-Value Observed: 0.183 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 51.95α = 90
b = 57.73β = 90
c = 75.56γ = 90
Software Package:
Software NamePurpose
X-PLORmodel building
X-PLORrefinement
X-PLORphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

  • Deposited Date: 1994-11-22 
  • Released Date: 1995-02-07 
  • Deposition Author(s): Ceccarelli, C.

Revision History  (Full details and data files)

  • Version 1.0: 1995-02-07
    Type: Initial release
  • Version 1.1: 2008-03-03
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2012-02-22
    Changes: Database references